Tag Archives: depression

Brexanolone (Zulresso) for Postpartum Depression Cleared by the DEA, Now Available

Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression.  At that time, we were told that Zulresso would be available in June 2019. Here are a few updates. The Drug Enforcement Administration (DEA) has recommended that brexanolone be placed in schedule IV of… Read More »

Exposure to Postpartum Depression Leads to Changes in Children’s Brain Development

Neuroimaging studies over the last few years have demonstrated that exposure to maternal depression can lead to changes in the architecture of the child’s brain, changes which may persist into adulthood and are associated with disruptions in cognitive development.  Less clear is how the timing of exposure may modulate the effects of maternal depression on… Read More »